摘要
Next-generationsequencing(NGS)hasbeenrapidlyintegratedintomolecularpathology,dramaticallyincreasingthebreadthgenomicofinformationavailabletooncologistsandtheirpatients.Thisreviewwillexplorethewaysinwhichthisnewtechnologyiscurrentlyappliedtobolstercareforpatientswithsolidtumorsandhematologicalmalignancies,focusingonpracticesandguidelinesforassessingthetechnicalvalidityandclinicalutilityofDNAvariantsidentifiedduringclinicalNGSoncologytesting.
出版日期
2016年01月11日（中国Betway体育网页登陆平台首次上网日期，不代表论文的发表时间）
